

# Abbreviated Curriculum vitae

## Andrew M Chancellor BHB, MBChB, MD, FRACP, FRCP

**Date of Birth** 1st June 1958 England.  
**Residence** 149 Crawford Road, Tauranga, New Zealand 3171  
**e-mail** [andrew.chancellor@bopdhb.govt.nz](mailto:andrew.chancellor@bopdhb.govt.nz) (DHB)  
**Telephone/txt** +64 7 (0)21473627  
**Nationality** Dual citizenship and passport holder - NZ and the UK.  
**Marital Status** Married, 2 Daughters (b 1989, 1996), one son (b 1983)  
**University** University Junior Scholarship, 1976-1981. Bachelor of Human Biology (BHB) 1979; Bachelor of Medicine and Bachelor of Surgery (MbChB) 1981, A pass. Doctor of Medicine (MD), 1994. (All degrees awarded by Auckland University, NZ).

### Current position (1994- )

- Specialist Neurologist, Tauranga, Bay of Plenty, NZ - part of medical services in NZ's 4<sup>th</sup> largest city and serving 220,000 persons, across 2 hospital sites.
- Ambulatory care and in-patient based general neurology and neurophysiology; dedicated multiple sclerosis clinics.
- Private consulting practice consulting since 1996.
- 1200 patient contacts/annum (approx.).

### Professional membership and affiliations/CPD programme\*

\*The Royal Australasian College of Physicians (1990); The Royal College of Physicians of London (2012); The Association of British Neurologists, overseas member; The Australian and New Zealand Association of Neurologists (ANZAN); Neurological Association of NZ (Past President 2012-13).

### Employment summary 1982-2017

---

HO/Medical Registrar	Auckland Area Health Board	1982-1986 (4.0 years)
Neurology Registrar	Auckland Area Health Board	1987-1988 (2.5 years)
Neurology Registrar	Lothian Health Board, Edinburgh	1989-1990 (1.5 years)
Research Fellow	University of Edinburgh	1991-1992 (2 years)
Senior Registrar	University Hospital of Wales	1992-1993 (15 months)
Consultant	Tauranga Hospital	1994-
Consultant, locum	DCN, Edinburgh	2003-2004 (12 months)

### Teaching, consultancy, community service

- Editorial Board member: Practical Neurology, (BMJ press) 2005 -
- Auckland Medical School student supervision and examiner.
- Convenor, annual Neurology Course for Registrars, 1996-2017 (faculty of 6 tutors with 42 delegates and 18 patient participants).
- Senior Examiner, Royal Australasian College of Physicians.
- Occasional consultancy for pharmaceutical industry (Biogen , Merck re MS treatments)
- Trustee Tauranga Girls' College 2010-2016
- Member St Peter's in the City, Tauranga

### Recent audits

- Annual NZ CJD reports - member of the National CJD Surveillance Unit, University of Otago and MOH.
- Ulnar neuropathy with non-localizing electrophysiology: clinical, electrophysiological and ultrasound findings 2016.
- BOPDHB Multiple Sclerosis clinic work/use of DMT, 2015 and 2016.

## Sample of publications in referred journals

1. Webster MWI, Chancellor AM, Smith HJ, Sharpe DN, Swift DL, Bass NM, Glasgow GL. Patent foramen ovale in young stroke patients. **Lancet** 1988; ii: 11-12.
2. Chancellor AM, Glasgow GL, Ockelford PA, Johns A, Smith J. Aetiology, prognosis and haemostatic function after cerebral infarction in young stroke patients. **Stroke** 1989; **20**: 477-482.
3. Chancellor AM, Cull RE, Kilpatrick DC, Warlow CP. Neurological disease associated with anticardiolipin antibodies in patients without systemic lupus erythematosus: clinical and immunological features. **J Neurol** 1991; **238(7)**: 401-407.
4. Chancellor AM. The epidemiology of Motor Neuron Disease in Scotland 1989-1990. A prospective study of incidence, clinical features and prognosis and incorporating a case-control study of antecedent environmental factors. **MD thesis**. The University of Auckland, New Zealand; 1992.
5. The Scottish Motor Neuron Disease Research Group. (Manuscript by Chancellor AM, Warlow CP). The Scottish motor neuron disease register; A prospective study of adult onset motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989. **J Neurol Neurosurg Psychiatry** 1992; **55**: 536-551.
6. Chancellor AM, Warlow CP. Adult onset motor neuron disease: Worldwide mortality, incidence and distribution since 1950. **J Neurol Neurosurg Psychiatry** 1992; **55**: 1106-1115.
7. De Belleruche J, Chancellor AM, King A, Hardy J, Lane R, Houlden H. Absence of linkage between chromosomes 21 loci and familial amyotrophic lateral sclerosis **J Med Genetics** 1993; **30**: 318.
8. Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Warlow CP. The prognosis of motor neuron disease: A prospective study based on the Scottish motor neuron disease register. **J Neurol**; **240**: 339-346.
9. Chancellor AM, Fraser H, Swingler RJ, Holloway SM, Warlow CP, for the Scottish Motor Neuron Disease Register. Clinical heterogeneity of familial motor neuron disease: report of 11 pedigrees from a population based study in Scotland. **J Neurol. Sci** 1994; **124** (Suppl): 75-76.
10. Chancellor AM, Fraser H, Slattery J, Warlow CP. Risk factors for motor neuron disease: A case-control study based on patients from the Scottish Motor Neuron Disease Register. **J Neurol Neurosurg Psychiatry**. 1993; **56**: 1200-1206.
11. Willison HJ, Chancellor AM, Veitch J, Kennedy PGE, Warlow CP. Immunoglobulin G subclasses are normal in motor neuron disease. **J Neurol Sci** 1994; **124**: 115-116.
12. Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false positive diagnosis of motor neuron disease. Lessons from the Scottish Motor Neuron Disease Register, **J. Neurol Neurosurg Psychiatry** 1996; **60**: 147-151
13. Chancellor AM. Diagnosing motor neuron disease (Editorial) *Br Med J* **312**; 654-656 1996.
14. IST Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischaemic stroke. **Lancet** 1997; **349**: 1569-1581.
15. O'Hanlon, Veitch J, Gallardo E, Illa I, Chancellor AM, Willison HJ. Peripheral Neuropathy Associated with Anti-GM2 ganglioside antibodies: Clinical and immunopathological studies. **Autoimmunity** 2000; **32**: 133-144.
16. Chancellor A, Addidle M, Dawson K. Multiple Sclerosis is more prevalent in northern NZ than previously reported. **J Int Med** 2003; **33**: 79-83.
17. Chancellor AM, McNaughton HK. Motor Neuron Disease, disorders of the spine and spinal cord. Chapter 10 in: **The Lancet handbook of Treatment in Neurology**. Ed C Warlow, Elsevier 2006.
18. Chancellor AM. Editorial: Electroencephalography: maturing gracefully **Pract Neurol** 2009;**9**:130-132.
19. Snow BJ et al, on behalf of the Protect Study Group. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. **Movement Disorders** 2010; **25**:1670-1674.
20. Szmulewicz DJ, Waterston JA, Halmagyi GM, Mossman S, Chancellor AM, McLean CA, Merchant S, Patrikios P, Storey E. Sensory neuropathy is an integral component of the cerebellar ataxia with bilateral vestibulopathy syndrome. **Neurology** 2011; **76**:1903-10.
21. Chancellor AM. A bitter-sweet tale from the land of milk and honey. **Pract Neurol** 2013;185-187.
22. Wu TY, Taylor JM, Kilfoyle DH, Smith AD, McGuinness BJ, Chancellor AM, et al. Autonomic dysfunction is a major feature of the cerebellar ataxia, neuropathy, vestibular areflexia "CANVAS" syndrome. **Brain** 2014;137:2649-56.
23. Chancellor A. Letter to the editor *Clinical Medicine* 2016 Vol 16 No 6, 607.
24. Pelosi L, Leadbetter R, Mulroy E, Chancellor AM, Mossman S, Roxburgh R. Peripheral nerve ultrasound in CANVAS. **Muscle and Nerve** 2016.